Topic 429 a new paradigm for autologous and allogeneic cell therapy manufacturing period of performance september 13, 2021-june 12, 2022 FY21 phase I sbir
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91021C00017
- Awardee
-
Proteios Technology, Inc. UEI G6QLLQD9UMT1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $455,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Pre-Solicitation · PHS20211 · Posted Jul 9, 2020
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proprosals Solicitation · Posted Jul 28, 2020
- Contract value 100% obligated
- $455,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 9 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Issaquah, WA, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $55,000 | |
| Other Administrative Action | $0 | |
| Original award | $400,000 |
About this award
This contract was awarded by the National Cancer Institute to Proteios Technology, Inc., a self-certified small disadvantaged business. The $455,000 firm-fixed-price contract is for a 1-year Small Business Innovation Research (SBIR) Phase I project focused on developing a new paradigm for autologous and allogeneic cell therapy manufacturing. The contract is part of the NCI's SBIR program, which aims to stimulate technological innovation and increase commercialization of federal research and development. Proteios Technology is a biotech company specializing in sustainable protein purification for the biopharmaceutical and cell therapy sectors. This SBIR Phase I award will support Proteios' research and development activities to advance cell therapy manufacturing processes.
Quick answers
Who was awarded contract 75N91021C00017?
75N91021C00017 was awarded to Proteios Technology, Inc. by National Cancer Institute (National Institutes of Health) on September 13, 2021.
How much is contract 75N91021C00017 worth?
The government has obligated $455,000 on 75N91021C00017.
Was contract 75N91021C00017 competed?
The extent of competition for 75N91021C00017 was full and open competition after exclusion of sources. The government received 9 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award